Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Transocean Ltd (RIG) vs GeneDx Holdings Corp (WGS) Price & Performance

Transocean LtdTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Transocean Ltd vs GeneDx Holdings Corp — how do they compare? Transocean Ltd trades at $5.75 (market cap $6.43B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: Transocean Ltd is far larger — about 2.5× GeneDx Holdings Corp's market cap, and Transocean Ltd is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.

RIGWGS
Market Cap
$6.43B$2.56B
Sector
TechnologyTechnology
52-Week High
$7.58$167.51
52-Week Low
$3.08$34.51
Enterprise Value
$11.04B$2.60B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Transocean Ltd

Transocean (RIG) trades at $5.76, down 1.54% today, with a bearish technical signal despite recent earnings beat. The company shows improving operational cash flow ($995M in 2026) and secured a $300M contract with ONGC, but faces challenges with negative net income margins (-40.24%) and high debt levels. Analyst sentiment is mixed with 39% buy ratings amid ongoing profitability concerns.

RIG presents a high-risk opportunity with improving contract backlog and cash flow generation potential offset by substantial debt burden and inconsistent earnings performance. Investors should weigh the company's exposure to volatile oil prices against its position in the tightening deepwater drilling market.

GeneDx Holdings Corp

WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.

Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Transocean Ltd

Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.

Read more on RIG

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS